DUBLIN – Woodford Patient Capital Trust plc and Malin Corp. plc have co-invested in a $50 million extension to Kymab Ltd.'s series B round, in a transaction that brings two more deep-pocketed investors into the Cambridge, UK-based antibody technology firm.